Aldeyra Therapeutics Inc. (ALDX)
Aldeyra Therapeutics Statistics
Share Statistics
Aldeyra Therapeutics has 59.71M shares outstanding. The number of shares has increased by 0.5% in one year.
| Shares Outstanding | 59.71M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0.27% |
| Owned by Institutions (%) | 62.31% |
| Shares Floating | 57.98M |
| Failed to Deliver (FTD) Shares | 675 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 3.76M, so 6.32% of the outstanding shares have been sold short.
| Short Interest | 3.76M |
| Short % of Shares Out | 6.32% |
| Short % of Float | 6.51% |
| Short Ratio (days to cover) | 8.72 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -15.64. Aldeyra Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -15.64 |
| PS Ratio | 0 |
| Forward PS | 1.6 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aldeyra Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.59, with a Debt / Equity ratio of 0.
| Current Ratio | 5.59 |
| Quick Ratio | 5.59 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 31.21 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-6,205.7B |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 54.37% in the last 52 weeks. The beta is 1.24, so Aldeyra Therapeutics's price volatility has been higher than the market average.
| Beta | 1.24 |
| 52-Week Price Change | 54.37% |
| 50-Day Moving Average | 6.1 |
| 200-Day Moving Average | 5.16 |
| Relative Strength Index (RSI) | 37.95 |
| Average Volume (20 Days) | 564.11K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -60,117B |
| Net Income | -55,851.4B |
| EBITDA | -60,117B |
| EBIT | -57,777.7B |
| Earnings Per Share (EPS) | -938919.68 |
Balance Sheet
The company has 54.53M in cash and 15.3M in debt, giving a net cash position of 39.22M.
| Cash & Cash Equivalents | 54.53M |
| Total Debt | 15.3M |
| Net Cash | 39.22M |
| Retained Earnings | -450,110.6B |
| Total Assets | 104.61M |
| Working Capital | 85.47M |
Cash Flow
In the last 12 months, operating cash flow was -43,208.7B and capital expenditures 0, giving a free cash flow of -43,208.7B.
| Operating Cash Flow | -43,208.7B |
| Capital Expenditures | 0 |
| Free Cash Flow | -43,208.7B |
| FCF Per Share | -726383.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ALDX is $10, which is 82.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 82.5% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.21 |
| Piotroski F-Score | 3 |